44
Impact of Systemic Anti-Inflammatory Therapy on Refractive Development and Myopia Progression in Pediatric Patients With Juvenile Idiopathic Arthritis
Based on findings presented by Summers JA, et al. at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting; May 3โ7, 2026; Denver, CO.
Background and Clinical Rationale
The global prevalence of pediatric myopia continues to increase, yet definitive pharmacologic or behavioral strategies to arrest axial elongation remain limited. Conventional paradigms have focused on optical and environmental inputs; however, emerging translational data indicate that inflammatory mediators may drive scleral biomechanical alterations and ocular growth.
Highlighting the limitations of current clinical modalities and the broader physiological context, study coauthor R. Michael Siatkowski, MD, MBA, chair of the Department of Ophthalmology at the University of Oklahoma, observed:
Preclinical animal models led by Jody A. Summers, PhD, professor at the University of Oklahoma, established the biochemical premise linking nonpathologic inflammatory signaling to axial elongation:
Study Design and Cohort Selection
To evaluate this mechanism in human populations, investigators designed a retrospective cohort study using longitudinal refractive records from 197 pediatric patients evaluated at the Dean McGee Eye Institute between October 1997 and November 2025.
Children diagnosed with juvenile idiopathic arthritis (JIA) were selected as a clinical model for chronic systemic immunotherapy exposure. Describing the selection strategy, Dr. Siatkowski stated:
Table 1. Study Population Architecture and Methodological Framework ($N = 197$)
| Parameter | Study Specification |
| Study Setting | Dean McGee Eye Institute, University of Oklahoma |
| Study Design | Retrospective longitudinal cohort analysis |
| Observation Window | October 1997 to November 2025 |
| Study Populations Evaluated | * Patients with JIA receiving chronic systemic anti-inflammatory therapy * Patients with untreated JIA (no systemic anti-inflammatory therapy) * Pediatric control subjects without systemic inflammatory disease |
| Key Inclusion Criterion for JIA Cohort | Long-term systemic immunosuppression/anti-inflammatory treatment without confounding ocular pathology (e.g., active uveitis) |
| Primary Evaluated Endpoint | Refractive status trajectory and longitudinal myopic progression across age intervals |
Refractive Outcomes and Trajectory Analysis
Children undergoing chronic anti-inflammatory treatment displayed marked protection against early-onset myopia compared with untreated individuals and controls. Pediatric patients with JIA managed with systemic anti-inflammatory agents demonstrated maintained hyperopic refractive error through adolescence, only shifting slightly into myopia around age 17.
Conversely, control subjects without anti-inflammatory exposure transitioned into myopia by approximately 10 years of age. Untreated patients with JIA exhibited the earliest onset and greatest degree of myopic progression.
Characterizing these divergent refractive paths, Dr. Summers noted:
Table 2. Comparative Longitudinal Refractive Trajectories by Cohort
| Study Cohort | Onset of Myopia | Longitudinal Refractive Profile | Relative Myopia Severity |
| JIA on Systemic Anti-Inflammatory Therapy | Delayed ($\approx$17 years of age) | Maintained hyperopia through childhood/early adolescence; minimal myopic transition late in development | Lowest (significantly mitigated progression) |
| Controls (No Anti-Inflammatory Therapy) | Typical childhood onset ($\approx$10 years of age) | Standard progressive childhood myopic shift | Intermediate |
| Untreated JIA Cohort | Accelerated onset (<10 years of age) | Accelerated, progressive myopic shift continuing through adolescence | Highest (most severe and earliest progression) |
Biomechanical Hypotheses and Future Directions
Rather than viewing ocular inflammation solely as a consequence of tissue stretching in advanced axial myopia, the investigators suggest that inflammatory cytokines directly alter scleral biomechanics.
Dr. Summers detailed this biomechanical hypothesis:
Targeting these pathways therapeutically remains an active area of investigation:
To expand on these findings, investigators are launching a larger multicenter regional cohort in Oklahoma. Dr. Siatkowski explained:
Disclosures
The authors reported no relevant financial disclosures.
